References

• Tan CH, Shinfuku N, Sim K. Psychotropic prescription practices in east Asia: looking back and peering ahead. Curr Opin Psychiatry 2008; 21(6): 645–50.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35(2): 443–57.
   PubMed Web of Science ®Google Scholar
• Ozalmete OA, Ceylan ME, Ozalmete O, Sevim ME. Yatan Şizofreni Hastalarında Coklu Antipsikotik Kullanımı. Noropsikiyatri Arşivi—Archives of neuropsychiatry 2010; 47(1): 23–8.
   Google Scholar
• Kahiloğulları AK, Orsel O, Sargın AE, Hatıloğlu U, Berber MS, Ozbay MH. Şizofrenide ilaç reçeteleme eğilimindeki değişiklikler. Klinik Psikofarmakoloji Bulteni—Bulletin of Clinical Psychopharmacology 2008; 18(3): 162–6.
   Google Scholar
• Yılmaz A, Soykan A, Gul ES, Saka MC. Hastanede yatan şizofreni ve şizoaffektif bozukluk tanılı hastalardaki antipsikotik tedavi secimlerinin geriye donuk değerlendirilmesi. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2007; 17(1): 9–14.
   Google Scholar
• Hatıloğlu U, Karadağ H, Akkoyunlu S, Guriz SO, Kahiloğulları AK, Orsel S. Şizofrenide ve Diğer Psikotik Bozukluklarda Coklu İlac Kullanımı: Uzun Etkili Antipsikotik İlacların Rolu. Klinik Psikiyatri Dergisi 2010; 13(3): 101–7 (Turkish).
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(Suppl 2): S1–S56.
   PubMed Web of Science ®Google Scholar
• National institude of clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Heath Technology Appraisal No: 43. 2002. www.nice.org.uk
   Google Scholar
• Ranceva N, Ashraf W, Odelola D. Antipsychotic polypharmacy in outpatients at Birch Hill Hospital: incidence and adherence to guidelines. J Clin Pharmacol 2010; 50(6): 699–704.
   Web of Science ®Google Scholar
• Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007; 68(11): 1751–62.
   PubMed Web of Science ®Google Scholar
• Pandurangi AK, Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 2008; 14(6): 345–67.
   Web of Science ®Google Scholar
• Ananth J, Parameswaran S, Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Des 2004; 10(18): 2231–8.
   PubMed Web of Science ®Google Scholar
• McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003; 64(9): 984–9.
   Web of Science ®Google Scholar
• Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9.
   PubMed Web of Science ®Google Scholar
• Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005; 5: 26.
   PubMed Web of Science ®Google Scholar
• Megna JL, Kunwar AR, Mahlotra K, Sauro MD, Devitt PJ, et al. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 2007; 13(2): 129–37.
   Google Scholar
• Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004; 65(12): 1597–600.
   PubMed Web of Science ®Google Scholar
• Karagianis J, Williams R, Davis L, Procyshyn R, Monga N, Hanley J, et al. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Curr Med Res Opin 2009; 25(9): 2121–32.
   PubMed Web of Science ®Google Scholar
• Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010; 71(5): 566–73.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2008; 23(6): 455–63.
   Web of Science ®Google Scholar
• Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005; 187: 243–7.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009; 2: 6.
   PubMedGoogle Scholar
• Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168(7): 702–8.
   PubMed Web of Science ®Google Scholar
• Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 2010; 32(5): 949–59.
   PubMed Web of Science ®Google Scholar
• Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, et al. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophr Res 2011; 130(1–3): 40–6.
   Web of Science ®Google Scholar
• Lerma-Carrillo I, de Pablo Bruhlmann S, del Pozo ML, Pascual-Pinazo F, Molina JD, Baca-Garcia E. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 2008; 31(6): 319–32.
   Web of Science ®Google Scholar
• Santone G, Bellantuono C, Rucci P, Picardi A, Preti A, de Girolamo G. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiol Drug Saf 2011; 20(5): 441–9.
   Web of Science ®Google Scholar
• Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161(4): 700–6.
   PubMed Web of Science ®Google Scholar
• Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007; 58(4): 482–8.
   PubMed Web of Science ®Google Scholar
• Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long- acting injections: prescribing practice in the UK. Br J Psychiatry 2009; 52(Suppl): S37–S42.
   Google Scholar
• Ghio L, Natta W, Gotelli S, Ferrannini L; Research Group. Antipsychotic utilization and polypharmacy in Italian residential facilities: a survey. Epidemiol Psychiatr Sci 2011; 20 (2): 171–9.
   PubMed Web of Science ®Google Scholar
• Nielsen J, le Quach P, Emborg C, Foldager L, Correll CU. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010; 122 (5): 356–66.
   Web of Science ®Google Scholar